--- title: "NEXGEL, INC. (NXGL) news: reverse split and convertible notes" url: "https://aibio.space/companies/nexgel/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "NXGL reverse split and convertible notes news: NexGel sets a 1-for-20 reverse stock split effective October 12, 2026. NEXGEL, INC." --- NXGL NEXGEL, INC. NASDAQ · United States # NEXGEL, INC. (NXGL) news NXGL reverse split and convertible notes news Listings · 2026-10-07 ## [NexGel sets a 1-for-20 reverse stock split effective October 12, 2026](https://aibio.space/news/nexgel-sets-1-20-reverse-stock-split-effective-october-12-2026/) Every 20 shares of common stock will combine into one share at 12:01 a.m. Eastern Time on October 12, 2026. The common stock will keep its Nasdaq Capital Market listing under NXGL with a new CUSIP. ## Latest NEXGEL, INC. news 1. 2026-08-21 Company Updates [NexGel names Brian Kieser interim CEO and forms a strategic review committee](https://aibio.space/news/nexgel-names-brian-kieser-interim-ceo-forms-strategic-review-committee/) Brian Kieser became interim chief executive on August 21, 2026, as Adam Levy left the role. A special committee will review non-core assets, liquidity and the company's long-term strategic direction. 2. 2026-07-23 Company Updates [NexGel signs a new employment agreement with CEO Adam Levy](https://aibio.space/news/nexgel-signs-new-employment-agreement-ceo-adam-levy/) The July 23, 2026 agreement sets a $375,000 base salary, EBITDA-linked bonus tiers and an option grant of 160,000 shares at $0.647 per share. 3. 2026-05-11 Debt Financing [NexGel issues $1,000,000 convertible note to new director Brian J. Kieser](https://aibio.space/news/nexgel-issues-1-000-000-convertible-note-new-director-brian-j-kieser/) The unsecured note converts at $0.60 a share and goes to Brian J. Kieser, a new director who runs Sequence LifeScience. Sequence bought $5,500,000 of notes in an earlier April financing. ## NEXGEL, INC. at a glance - **Ticker**: NXGL - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $1.7 million ### Related companies - [Vivos Therapeutics](https://aibio.space/companies/vivos-therapeutics/) NASDAQ: VVOS - [Nano-X Imaging](https://aibio.space/companies/nano-x-imaging/) NASDAQ: NNOX - [AGILENT TECHNOLOGIES, INC.](https://aibio.space/companies/agilent-technologies/) NYSE: A - [Sensus Healthcare](https://aibio.space/companies/sensus-healthcare/) NASDAQ: SRTS - [REVVITY, INC.](https://aibio.space/companies/revvity/) NYSE: RVTY - [20/20 Biolabs](https://aibio.space/companies/20-20-biolabs/) NASDAQ: AIDX - [ICU MEDICAL INC/DE](https://aibio.space/companies/icu-medical-de/) NASDAQ: ICUI - [INTEGRA LIFESCIENCES HOLDINGS CORP](https://aibio.space/companies/integra-lifesciences/) NASDAQ: IART ### Also on NASDAQ - [Personalis](https://aibio.space/companies/personalis/) PSNL - [AETHLON MEDICAL INC](https://aibio.space/companies/aethlon-medical/) AEMD - [Assembly Biosciences](https://aibio.space/companies/assembly-biosciences/) ASMB - [Dianthus Therapeutics](https://aibio.space/companies/dianthus-therapeutics/) DNTH - [Anbio Biotechnology](https://aibio.space/companies/anbio-biotechnology/) NNNN - [Kailera Therapeutics](https://aibio.space/companies/kailera-therapeutics/) KLRA ## NEXGEL, INC. annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$11.4 million](https://www.sec.gov/Archives/edgar/data/1468929/000149315226014377/) | [$8.7 million](https://www.sec.gov/Archives/edgar/data/1468929/000149315226014377/) | | Research and development | [$2,000](https://www.sec.gov/Archives/edgar/data/1468929/000149315226014377/) | [$78,000](https://www.sec.gov/Archives/edgar/data/1468929/000149315226014377/) | | Net income (loss) | [-$3.0 million](https://www.sec.gov/Archives/edgar/data/1468929/000149315226014377/) | [-$3.3 million](https://www.sec.gov/Archives/edgar/data/1468929/000149315226014377/) | | Cash from operations | [-$1.3 million](https://www.sec.gov/Archives/edgar/data/1468929/000149315226014377/) | [-$3.9 million](https://www.sec.gov/Archives/edgar/data/1468929/000149315226014377/) | | Cash and equivalents | | [$1.8 million](https://www.sec.gov/Archives/edgar/data/1468929/000149315225021738/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $1.7 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about NEXGEL, INC. Did NEXGEL, INC. do a reverse stock split? Our latest story on this, dated Oct 7, 2026: "NexGel sets a 1-for-20 reverse stock split effective October 12, 2026". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/nexgel-sets-1-20-reverse-stock-split-effective-october-12-2026/). Has NEXGEL, INC. sold convertible notes? Our latest story on this, dated May 11, 2026: "NexGel issues $1,000,000 convertible note to new director Brian J. Kieser". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/nexgel-issues-1-000-000-convertible-note-new-director-brian-j-kieser/). What is the ticker symbol of NEXGEL, INC.? NEXGEL, INC. trades under the ticker NXGL on NASDAQ. Where is NEXGEL, INC. listed? NEXGEL, INC. is listed on NASDAQ. Which country or territory is NEXGEL, INC. listed under? Our directory records NEXGEL, INC. under United States. Does aibio.space cover NEXGEL, INC.? aibio.space lists NEXGEL, INC. among 2,820 public biotech companies and publishes its news here as stories appear. What was NEXGEL, INC.'s revenue last year? $11.4 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is NEXGEL, INC. profitable? NEXGEL, INC. reported a net loss of $3.0 million for the fiscal year ended Dec 31, 2025, and used $1.3 million of cash in operations, per its annual report to the SEC. How much does NEXGEL, INC. spend on research and development? $2,000 in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does NEXGEL, INC. have? $1.7 million in cash at Jun 30, 2026, per its 10-Q. What is the latest NEXGEL, INC. (NXGL) stock news? Our latest story on NEXGEL, INC., dated Oct 7, 2026: "NexGel sets a 1-for-20 reverse stock split effective October 12, 2026". Every 20 shares of common stock will combine into one share at 12:01 a.m. Eastern Time on October 12, 2026. The common stock will keep its Nasdaq Capital Market listing under NXGL with a new CUSIP. [Source](https://aibio.space/news/nexgel-sets-1-20-reverse-stock-split-effective-october-12-2026/). How can I follow NEXGEL, INC. (NXGL) news? Press Follow on this page to add NEXGEL, INC. to your Following list, or subscribe to the aibio.space newsletter. We have published 4 stories naming NEXGEL, INC. so far, in Company Updates, Debt Financing, Listings. ## Investor discussion: NEXGEL, INC. Members talk about NEXGEL, INC. (NXGL). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at NEXGEL, INC., newest first. Each line links the filing it comes from. 1. 2026-10-07 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1468929/000149315226046154/form8-k.htm) 2. 2026-09-23 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1468929/000149315226043955/form8-k.htm) 3. 2026-08-24 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1468929/000149315226039890/formdef14a.htm) 4. 2026-08-17 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1468929/000149315226038553/formnt10-q.htm) 5. 2026-08-14 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1468929/000149315226038520/formpre14a.htm) 6. 2026-08-05 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1468929/000149315226036206/form8-k.htm) 7. 2026-06-09 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1468929/000149315226027965/formdef14a.htm) 8. 2026-05-29 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1468929/000149315226026453/formpre14a.htm) 9. 2026-04-30 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 5.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1468929/000149315226020657/ex99-1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:NXGL on TradingView](https://www.tradingview.com/symbols/NASDAQ-NXGL/). ## Listing details NEXGEL, INC. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker NXGL, recorded under United States. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: NEXGEL, INC. - **Ticker**: NXGL - **Listing**: NASDAQ - **Country or territory**: United States Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/nexgel/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "NEXGEL, INC. (NXGL) news: reverse split and convertible notes", 2026-10-31, https://aibio.space/companies/nexgel/